Loading stock data…
KYMR
$80.71-0.36 (-0.44%)
After Hours$81.07+0.36 (+0.45%)· Last close May 1
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kymera Therapeutics, Inc. in the Healthcare sector is trading at $80.71. The stock is currently 22% below its 52-week high of $103.00, remaining 20.1% above its 200-day moving average. Technical signals show neutral RSI of 31 and bearish MACD signal, explaining why KYMR maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 31) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$80.71
Potential Upside
5%
Whystock Fair Value$84.75
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Mean target$118.86+47.3%
Range$91.00 – $140.00
Fundamentals
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.44%
Volume
Today's trading volume
665,428
Recent News
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.
Kymera Therapeutics Q1 Earnings Call Highlights
Kymera Therapeutics (NASDAQ:KYMR) highlighted progress across its clinical-stage pipeline and provided a financial update during its first-quarter 2026 results call, with executives emphasizing execution of ongoing Phase 2b studies for KT-621 and upcoming clinical readouts for the IRF5 degrader KT-5
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of +20.40% and +211.90%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of +61.31% and +256.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration Progress
The latest move in Kymera Therapeutics (KYMR) stock has been driven by the FDA granting Fast Track designation to KT-621 for moderate to severe eosinophilic asthma, along with progress in its expanded collaboration with Gilead Sciences. See our latest analysis for Kymera Therapeutics. Despite a 2.6% one day share price decline and a 3.2% seven day share price pullback, Kymera’s recent regulatory milestones and partner progress come after a 19.5% 90 day share price return and a very large 1...